Introduction {#s1}
============

Airway inflammation and airway hyperresponsiveness (AHR) are both indispensable features of asthma ([@B21]). AHR can be defined as an exaggerated response of the airways to a variety of stimuli, such as histamine, methacholine, or cold air that result in airway obstruction ([@B122]; [@B96]). Persistent allergen challenge that correlates with chronic airway inflammation sustained by mediators released by infiltrating as well as resident cells, will ultimately lead to airway remodeling ([@B86]; [@B72]; [@B158]). Airway remodeling, a collective term for the structural changes of the asthmatic airway, can be characterized by increased airway smooth muscle (ASM) mass, goblet cell hyperplasia and subepithelial fibrosis ([@B47]). The ASM has been identified as the principal regulator of AHR in asthma due to its increased contractibility and mass in response to inflammatory mediators ([@B65]; [@B93]). Studies have demonstrated that the thickened layer of ASM causes airway narrowing (structural changes) as well as exaggerated ASM shortening (contraction) in response to contractile agonists ([@B67]; [@B109]). These findings suggest that increased ASM mass contributes both directly and indirectly to AHR, hence associated with the severity of asthma. The clinical usage of bronchial thermoplasty (BT) therapy reflects the importance of ASM hyperplasia in severe asthma. BT is a Food and Drug Administration (FDA) approved endoscopic therapy for severe and persistent asthma (refractory asthma) ([@B95]) that delivers radio frequency thermal energy to the airways through catheterization of the proximal bronchus ([@B41]). BT is applied mainly to reduce ASM mass, thus reducing the bronchospasms and AHR ([@B123]). Furthermore, there is evidence demonstrating that BT is also capable of reducing airway inflammation ([@B36]). There have been controversial views regarding the application of BT which include lack of understanding of the underlying mechanism of action coupled with fact that some asthmatics are unresponsive to the treatment ([@B40]; [@B41]; [@B95]). [@B40] demonstrated that BT failed to reduce ASM hyperplasia in a patient with severe persistent asthma. This study highlighted the need to increase the temperature applied for BT to reduce ASM and the need to further study the effect of BT on ASM ablation especially in severe asthmatic patients. Nevertheless, BT still remains as an approved therapeutic option for refractory asthma that is non-responsive towards standard asthma treatment.

Effects of Current Asthma Medicines {#s2}
===================================

Current asthma therapies act mainly by attenuating ASM contraction and suppressing airway inflammation with minimal effects upon prevention and/or reversal of ASM remodeling ([@B71]). Combination therapy with inhaled corticosteroids (ICS) and long-acting β agonists (LABAs) remains the mainstay pharmacotherapeutic approach in asthma management ([@B162]). ICS are effective in suppressing inflammation while LABAs act as bronchodilators ([@B28]). Airway remodeling is thought to be a secondary event in asthma following persistent airway inflammation. However, [@B9] demonstrated that the airway remodeling occurs in asthmatic children in the absence of eosinophilic inflammation. Furthermore, young children with chronic asthma have detectable markers of airway remodeling and inflammation ([@B91]). These findings suggest that airway remodeling may occur in parallel with airway inflammation. Therefore, therapy that can reverse or inhibit both airway inflammation and airway remodeling would be of great benefit in the management of asthma. The therapeutic effect of combined ICS and LABA treatment in reversing ASM remodeling remains controversial. In an equine asthma model, combination treatment with corticosteroids and LABAs and corticosteroids alone were demonstrated to decrease ASM hyperplasia ([@B19]). *In vitro* studies with human cells demonstrated that combined corticosteroid and LABA treatment was ineffective in preventing or reversing remodeling events such as extracellular matrix (ECM) deposition and the release of interleukin-6 (IL-6) in both asthmatic and non-asthmatic ASM cells ([@B53]), whereas omalizumab, an anti-IgE mAb, when used as an add-on treatment to corticosteroids and LABA, was shown to reduce both airway inflammation and airway remodeling ([@B66]). Alternatively, treatment with the corticosteroid dexamethasone caused mix responses in terms of its inhibitory effect upon mitogen-induced ASM proliferation in human non-asthmatic ASM cells ([@B48]; [@B15]; [@B117]). An in-depth understanding of the underlying mechanism of increased ASM mass is therefore crucial for the development of therapeutic strategies that directly target altered ASM physiology leading to more effective management of asthma.

Other less commonly used treatment modalities in the management of asthma include leukotriene receptor antagonists (LTRAs), anticholinergics and monoclonal antibody (mAb) therapies appear. The action of LTRAs results in both bronchodilator and anti-inflammatory effects whereby anticholinergics, particularly long-acting muscarinic antagonists (LAMAs), work as bronchodilators ([@B35]; [@B92]). Treatment with a combination of oral LTRA, such as montelukast with ICS and LABA was shown to improve airway function, but not airway remodeling in moderate-to-severe asthma patients ([@B51]), whereas tiotropium bromide, a LAMA, has been demonstrated to inhibit ASM remodeling in a guinea pig model of allergic asthma ([@B57]). The first mAb therapy approved for asthma treatment was omalizumab which is effective in neutralizing the IgE-mediated allergic cascade in asthma ([@B34]; [@B92]). IgE has been suggested to also induce proliferation and secretion of proinflammatory cytokines in human non-asthmatic ASM cells and omalizumab has been reported to significantly attenuate these effects ([@B133]; [@B128]; [@B134]).

The role of T cells in the pathophysiology of asthma is well documented. The role of the T helper 17 (Th17) cell and its cytokine in airway remodeling has been reported and reviewed in recent years ([@B116]; [@B58]; [@B23]). The Th17 cytokine IL-17 has been shown to induce bronchial epithelial cells to produce insulin-like growth factor-І (IGF-І), which is known to induce collagen formation as well as ASM hyperplasia ([@B56]; [@B108]; [@B70]). Furthermore, a previous study has demonstrated that IL-17 acts upon human bronchial fibroblasts to produce cytokines, such as growth-related oncogene alpha (Gro-α)/CXCL1, which was reported to inhibit human airway smooth muscle cell migration ([@B97]; [@B4]; [@B116]). In addition, the anti-IL-17 mAb has been shown to reduce the levels of several remodeling markers, which include TGF-β, fibronectin, collagen fibers І and MMP-9, in a murine asthma model ([@B23]). Th17-associated cytokines have been demonstrated to induce ASM cell proliferation, migration, and reduced ASM cell apoptosis ([@B27]; [@B26]), suggesting that Th17-associated cytokines possibly contribute to ASM hyperplasia in asthma. T helper 2 (Th2) cells on the other hand have been recognized for their role in mediating IgE synthesis through production of interleukin (IL)-4 and IL-13 ([@B131]). Inhibition of the Th2 cytokine IL-13 with an anti-IL-13 mAb has been shown to inhibit airway remodeling in a chronic mouse model of asthma ([@B14]; [@B160]). Furthermore, Th2 cytokines were shown to enhance ASM proliferation and migration leading to ASM remodeling ([@B119]; [@B103]). Since both Th2 and Th17 cells play a significant role in ASM hyperplasia, mAb therapy targeting both Th2 and Th17-associated cytokines has good potential in reducing ASM remodeling in asthma.

Mechanism of Increased ASM Mass {#s3}
===============================

Increased ASM mass can result from hyperplasia and/or hypertrophy. ASM hypertrophy is reported to be present in both fatal and non-fatal asthma while ASM hyperplasia is predominantly detected in cases of fatal asthma ([@B68]). This suggests that an increase in ASM cell number, possibly due to proliferative responses, is more likely to contribute to the severity of asthma. Increased ASM mass has been linked to increased ASM proliferation and migration and diminished ASM apoptosis ([@B111]; [@B10]). Higher expression of cellular proliferation markers (PCNA and/or Ki-67) coincide with increased ASM cell proliferation rates in asthmatic patients ([@B157]; [@B62]; [@B125]). Alternatively, opposing arguments claim no differences in the number of PCNA and/or Ki-67 positive ASM cells between human asthmatic and non-asthmatic airways ([@B67]; [@B106]). [@B67] claim that discrepancies could stem from the variation that occurs during data collection. In addition, the findings reported by [@B67] have demonstrated that there was no correlation between PCNA- and cyclin D-positive cells. Besides, PCNA has been reported to be upregulated for its role in DNA repair and chromatin remodeling, implying the expression of PCNA could increase due to DNA repair or chromatin remodeling without any increment in cell number ([@B89]). Therefore, the sensitivity of these molecules (Ki-67, PCNA and cyclin D) as proliferation markers has been questioned by [@B67]. Indeed, these discrepancies could also be explained by the different half-life of these proliferative markers. PCNA has a reported half-life of 20 h, whereas Ki-67 has a much shorter half-life, which is only around 60--90 min *in vitro* ([@B17]; [@B18]; [@B64]). In addition, cyclin D has a rather short half-life, which is less than 30 min *in vitro* ([@B37]; [@B69]). These findings suggest that collection of tissue samples should be done within a short period of time and PCNA could be a more stable proliferative marker as compared to Ki-67 and cyclin D. Furthermore, as reviewed by [@B8] based on the report summarized by [@B75], the lack of staining of PCNA/Ki-67 in asthmatic airways could be due to the increased cellular proliferation that may have occurred prior to obtaining a biopsy. Nevertheless, compounding cellular dynamics such as ASM migration and/or diminished apoptosis in response to the inflammatory mediators could explain these variations.

The Role of Inflammation on ASM Abundance {#s4}
=========================================

Numerous investigations have employed *in vitro* models to assess the role of inflammatory mediators in increasing ASM cell proliferation ([@B22]; [@B136]). A wide range of inflammatory mediators and growth factors released during an asthma attack were reported to induce ASM cell proliferation *in vitro* ([@B59]; [@B141]; [@B1]; [@B76]). Among these mediators, IL-8, eotaxin, and MIP-1α have been shown to reduce the rate of apoptosis in human non-asthmatic ASM cells ([@B59]). Transforming growth factor beta-1 (TGF-β1) has been shown to be elevated in the asthmatic airway and its regulatory role in airway remodeling has been intensively reviewed ([@B129]; [@B150]; [@B24]; [@B90]; [@B60]; [@B2]). TGF-β1 was reported to induce both ASM proliferation and migration ([@B83]; [@B44]; [@B52]; [@B85]) and reduces ASM apoptosis as well ([@B44]; [@B52]). In a study that employed human non-asthmatic ASM cells microRNA-217 (miR-217) was shown to inhibit TGF-β1-induced ASM proliferation and migration but promoted apoptosis in TGF-β1-induced ASM through a similar signaling molecule, namely zinc finger E-box binding homeobox 1 (ZEB1) ([@B52]). [@B167] demonstrated enhanced miR-146a expression inhibits epidermal growth factor receptor (EGFR) with suppression of proliferation and increased rates of apoptosis in human ASM cells. Similarly, miR-142 was demonstrated to inhibit proliferation and promote apoptosis in ASM cells isolated from asthmatic rats through a mechanism that involved TGF-β1-dependent EGFR signaling ([@B153]). Furthermore, inhibitors of EGFR and p38 have been shown to inhibit migration of ASM cells from allergen sensitized and challenged mice ([@B154]). The role of p38 in mediating actin cytoskeleton remodeling in ASM cells is dependent upon heat shock protein 27 (HSP27) that acts as a downstream substrate for p38 and regulator of cytoskeletal remodeling in ASM ([@B63]; [@B6]). These reports suggest a dynamic interrelationship between rates of ASM proliferation, apoptosis, and migration that could possibly be regulated through similar pathways.

Signal Transduction Regulation in ASM Proliferation {#s5}
===================================================

ASM proliferates in response to growth factors, inflammatory cytokines, and contractile agonists that activate receptor tyrosine kinases (RTKs), G-protein coupled receptors (GPCRs) and non-receptor tyrosine kinases (nRTKs) ([@B79]). In addition, free fatty acids also activate both GPCRs and nRTKs to cause proliferation with a possible association between obesity and increased ASM mass in human non-asthmatic ASM ([@B94]). Activation of RTKs and GPCRs stimulate the activation of Ras, a small guanosine triphosphatase (GTPase) protein, which is known to stimulate both mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K)/AKT pathways that promote ASM proliferation ([@B149]). The three main MAPK signaling pathways; ERK, c-jun N-terminal kinase (JNK) and p38, as well as the PI3K/AKT signaling pathway are well-recognized as major mitogenic pathways involved in ASM proliferation ([@B80]; [@B49]; [@B74]; [@B20]; [@B59]; [@B31]). Among these proliferation pathways, [@B151] demonstrated that the PI3K pathway is the key signaling route in ASM proliferation while the ERK pathway provides a complementary signal required for the full mitogenic response in bovine non-asthmatic ASM cells. The inhibitor (LY294002) of the PI3K signaling pathway completely abolished PDGF-BB and thrombin-induced DNA synthesis in bovine non-asthmatic ASM cells, whereas the inhibitor of ERK (PD98002), at a concentration that completely inhibits ERK kinase activity, only partially inhibited DNA synthesis in bovine non-asthmatic ASM. Indeed it has been shown that in response to strong mitogenic stimuli, such as 10% foetal bovine serum (FBS), MAP kinase phosphatase-1 (MKP-1), a MAPK phosphatase, is up-regulated in human asthmatic ASM cells leading to a reduction of ERK activation and subsequently causing a shift of the mitogenic role to the PI3K pathway alone ([@B20]). In response to induction with FBS it has been shown that both PI3K and ERK pathways are involved in non-asthmatic and asthmatic ASM cell proliferation, although strong stimuli (10% FBS) causes a reduction of ERK activation in inducing asthmatic ASM proliferation. These findings suggest that therapeutic intervention through targeted disruption of the PI3K pathway rather than the ERK pathway could be more effective in reversing or inhibiting increased ASM mass.

Whereas activation of Ras induces full activation of ERK and modest activation of stress-induced MAPKs (JNK and p38) in bovine ASM ([@B113]), Ras-related C3 botulinum toxin substrate 1 (Rac1), another small GTPase, is reported to induce full activation of JNK and p38 without any effect upon ERK activation in smooth muscle cells ([@B113]; [@B81]). These findings suggest that both Ras-MAPKs and Rac-JNK/p38 pathways are involved in ASM proliferation with possibly varying influences. Upon activation of ERK, JNK and PI3K/AKT signaling pathways, expression of cyclin D1, a key cell cycle regulator, is up-regulated ([@B115]; [@B127]; [@B31]), leading to ASM proliferation, whereas p38 induces proliferation in human ASM cells through the phosphorylation of retinoblastoma protein (pRb) instead of cyclin D1 ([@B49]). Furthermore, PDGF-induced activation of p38 in bovine ASM cells has been demonstrated to negatively regulate cyclin D1 expression leading to inhibition of ASM proliferation ([@B112]). These contradictory findings on the role of p38 in ASM proliferation could be due to the nature of the mitogenic stimuli, a dual role of p38 and/or different species. A dual role of p38 in cellular proliferation has been reported in fibroblasts, in which the level of p38 activation in response to different stimuli determines either mitogen-induced proliferation or stress-induced cell cycle arrest as a cellular response ([@B46]). Furthermore, the mitogenic effect of p38 in inducing ASM proliferation has been demonstrated to be mitogen-specific in which basic fibroblast growth factor (bFGF), but not thrombin, induced p38 phosphorylation whereas both stimuli were equally effective in inducing pRb phosphorylation and subsequent ASM proliferation ([@B49]).

Recently the role of microRNA in regulation of major proliferative pathways signaling has been demonstrated. PI3K and JNK signaling pathways can be co-regulated through microRNA-708 in which its overexpression was shown to induce expression of PTEN, a tumor suppressor, resulting in a reduction of AKT phosphorylation, a downstream target in PI3K pathway in human ASM cells ([@B38]). Furthermore, microRNA-708 has also been shown to decrease the phosphorylation of JNK in human ASM cells and this effect was associated with an increased expression of MKP1 ([@B38]). In contrast, increased MKP1 expression was not associated with decreased p38 phosphorylation which is inconsistent with previous findings that MKP1 can dephosphorylate both JNK and p38 ([@B147]; [@B38]). This could be due to compensatory upregulation of several upstream kinases involved in the phosphorylation of p38.

Several studies in various cell types have demonstrated convergence of both PI3K and JNK signaling pathways. A study in human bronchial epithelial cells involving overexpression of mutant p85 (PI3K) and dominant-negative AKT demonstrated that PI3K and AKT both act as upstream regulators of JNK and c-Jun, suggesting a PI3K/AKT/JNK/c-Jun/cyclin D signaling pathway in the regulation of cell proliferation ([@B39]). In HeLa cells the PI3K inhibitor wortmannin inhibited EGF-induced JNK activation while no inhibitory effect was detected following UV- or osmotic stress-induced JNK activation, suggesting PI3K acts as an upstream activator in mediating mitogenic-induced JNK activation ([@B87]). Conversely, JNK was reported to act as an upstream activator of AKT in serotonin (5-HT)-induced pulmonary artery smooth muscle cells (PASMCs), whereby inhibition of JNK was shown to suppress the activation of AKT, subsequently inhibiting PASMCs proliferation ([@B155]). Since, as discussed earlier, JNK is suggested to have other upstream activators in ASM cells and coupled with evidence of interplay between JNK and PI3K/AKT pathways in PASMCs and cancer cells, the existence of crosstalk between these two pathways in regulating ASM cell proliferation cannot be ruled out. Further investigations into the probable interplay between these two pathways in ASM proliferation would therefore yield crucial information for the development of more selective and safer drugs.

The JAK2/STAT3 pathway also plays a major role in ASM mitogenesis. This pathway was demonstrated to contribute to the mitogenesis of PDGF-induced ASM. Several cell cycle regulators such as cyclin D1, cyclin D3, and p27^Kip1^, Rac1 as well as c-myc, a proto-oncogene, are regulated through the activation of STAT3 in human ASM cells, thus inducing ASM proliferation ([@B139]; [@B138]). The role of the transcription factor STAT3 in ASM proliferation was further confirmed with the use of STAT3-short hairpin RNA (shRNA) transfected ASM cells, whereby STAT3-shRNA fully abrogated the proliferative effect of IgE and PDGF upon ASM cells ([@B128]). To date, studies have demonstrated that STAT3 can be phosphorylated by multiple upstream molecules which include RTKs, nRTKs, (Src and JAK2) as well as downstream kinases of MAPKs and PI3K in cancer cells ([@B13]). Some of these findings were observed in human ASM cells as well, whereby nRTKs such as Src and JAK2, and RTK growth factor, such as PDGF, were reported to mediate STAT3 activation ([@B139]; [@B138]). In addition to this, inhibition of ERK has also been demonstrated to inhibit IL-17-induced STAT3 phosphorylation in human ASM cells suggesting a functional role of ERK-STAT3 crosstalk ([@B135]). Furthermore sh-RNA silencing of STAT3 has been demonstrated to completely abolish IgE- and PDGF-mediated proliferation in human ASM cells ([@B128]). These observations suggest that STAT3 plays a major role downstream of most of the signaling pathways or receptors involved in ASM proliferation.

In recent years, the role of semaphorins (Sema) as therapeutic targets in airway disease has been addressed ([@B98]). Semaphorins are originally recognised as neuronal chemorepellents and were reported to play a role in cellular activities, such as cell proliferation, migration, adhesion, and angiogenesis ([@B99]). Increased AHR, airway remodeling and Th2/Th17 inflammation in chronic allergic airway disease were shown to be significantly augmented in a Sema 3E-deficient mouse model ([@B101]) and therefore demonstrating an essential role of Sema 3E in suppressing hallmarks of chronic airway disease. Sema 3E and 3A expression and their receptors were reported to be expressed in both human asthmatic and non-asthmatic ASM. Further investigations revealed that PDGF-induced ASM proliferation can be inhibited with exogenous Sema 3E and 3A in both non-asthmatic and asthmatic ASM cells ([@B100]; [@B102]). The inhibition was reported to be associated with several key proliferative signaling molecules. It is possible that semaphorin inhibition of ASM proliferation could be through its effects upon PDGFR as an upstream molecule. Both Semaphorins 3A and 3E decrease Rac1 GTPase activity in ASM. Furthermore, Sema 3A decreases the phosphorylation of PDGF-induced PDGFR and STAT3 in both human non-asthmatic and asthmatic ASM cells while Sema 3E was reported to decrease the phosphorylation of AKT and ERK1/2 ([@B100]; [@B102]). Further work is needed to fully address the functional role of Sema 3E upon PDGFR. Crosstalk between signaling pathways in the regulation of ASM proliferation is illustrated in [**Figure 1**](#f1){ref-type="fig"}.

![Crosstalk between proliferative signaling pathways in ASM. Inflammatory mediators, growth factors and contractile agonists released during asthma inflammation, induce ASM proliferation through activation of MAPKs, PI3K/AKT, and JAK2/STAT3 signaling pathways. AKT is suggested to act as the upstream activator of STAT3, a transcription factor. Besides, JNK may acts as the upstream activator or downstream target of AKT. Further investigation should be carried out to map out the association between AKT and JNK. Activation of these signaling molecules will increase the protein expression of cyclin D1 and subsequently induce the cell cycle progression. Solid arrows indicate the associations reported earlier while dotted arrows indicate the possible association that may occur, in which further examination need to be carried out.? Indicates the inconsistent findings.](fphar-10-01148-g001){#f1}

Signal Transduction Regulation in ASM Migration {#s6}
===============================================

Migration of ASM cells is accomplished through five main steps namely; cell polarization, protrusion, adhesion, contraction, and retraction. These steps are controlled by specific signaling molecules in response to stimuli such as growth factors, cytokines, chemokines, and the extracellular matrix (ECM) ([@B136]). Cellular migration is initiated *via* activation of RTKs, GPCRs, and matrix adhesive proteins, particularly integrins, which consequently activate remodeling of the cytoskeleton and rearrangement of subcellular organelles. Cytoskeletal remodeling is initiated with actin polymerization through activation of multiple signaling molecules which include Src, phospholipase C, c-Abl, phosphatidylinositol 4,5-bisphosphate (PIP~2~), and PI3K, leading to the activation of AKT, Rho, Ras, PKA, Cortactin, Cdc42, focal adhesion kinase (FAK), and myosin light chain kinase (MLCK) that in turn regulate cell polarization, actin polymerization, and traction force ([@B55]). This process will extend the leading edge (anterior) of a migrating cell protruding towards the stimuli through focal contacts and enhance attachment of the cell membrane to the ECM, while myosin motors will bind to actin filaments and generate traction force at the posterior end that moves the cell forward ([@B54]; [@B136]).

Various signaling molecules including FAK, PI3K, PTEN, ERK, p38, Src, Rho kinase, c-Abl, and Wnt/β-catenin have been reported to be involved in the regulation of ASM cell migration in response to migratory stimuli ([@B118]; [@B120]; [@B77]; [@B33]; [@B45]). However, the exact regulatory mechanism involved remains unclear. FAK, a nRTK, has been recognized as the key signaling molecule implicated in integrin pathways which are known to regulate cytoskeletal organization during cell migration. FAK regulates ASM migration through its interaction with several signaling molecules including PI3K, Src and Rho kinase ([@B118]; [@B120]; [@B77]; [@B170]; [@B33]; [@B45]). Furthermore, FAK is reported to be co-regulated with phosphatidylinositol 3,4,5-trisphosphate (PIP~3~), a product of the PI3K signaling molecule, through PTEN. Overexpression of PTEN dephosphorylates both PIP~3~ and FAK, hence significantly inhibiting ASM migration. This suggests that PTEN may not only be involved in the regulation of ASM cell proliferation, but also in the regulation of ASM cell migration ([@B146]; [@B77]).

Conflicting reports exist regarding the role of p38 in ASM cell migration. Using chemokines CXCL2 and CXCL3 as inducers, [@B3] demonstrated that PI3K plays a major role in the migration of human asthmatic ASM cells whereas ERK and p38 were shown to affect the migration of normal ASM cells without any effect upon asthmatic ASM cells. However, upon activation with EGFR, p38 was demonstrated to be involved in asthmatic ASM cell migration while specific inhibitors of p38 and EGFR prevented cellular migration ([@B154]). These inconsistent findings may be due to the effects of different stimuli upon cellular migratory pathways. The role of p38 in mediating actin cytoskeleton remodeling in ASM cells is dependent upon heat shock protein 27 (HSP27) that acts as a downstream substrate for p38 and regulator of cytoskeletal remodeling in ASM ([@B63]; [@B6]).

The nRTK c-Abelson tyrosine kinase (c-Abl) has been detected in the leading edge of human ASM cells ([@B33]). Silencing of c-Abl inhibited adhesion-induced phosphorylation of cortactin and localization of profilin-1 (Pfn-1) at the cell edge. Pfn-1 is a key enzyme that catalyzes actin elongation and polymerization ([@B73]). Phosphorylated cortactin recruits Pfn-1 to the leading edge and promotes localized actin filament rearrangement, leading edge formation and cell migration. Inhibition of cortactin phosphorylation and Pfn-1 localization upon silencing of c-Abl results in the inhibition of ASM migration and therefore suggests that c-Abl is possibly involved in the regulation of smooth muscle migration *via* cortactin and Pfn-1. The role of Wnt/β-catenin has also been reported in the regulation of migration in ASM cells isolated from rats ([@B45]). Increased expression of both β-catenin mRNA and protein has been demonstrated in the ASM of chronic asthmatic rats. Silencing of β-catenin significantly inhibited ASM migration, suggesting that β-catenin may be involved in the regulation of ASM migration and the pathology of asthma.

Recent studies have demonstrated the role of the sonic hedgehog (SHH) pathway in smooth muscle cell (SMC) migration. Particulate matter 2.5 (PM2.5), which is particulate matter with an aerodynamic diameter smaller than 2.5 µm, has been shown to induce migration of human ASM cells *via* the SHH pathway ([@B163]). This pathway plays a major role in developmental processes ([@B32]) and several studies have demonstrated that the activation of the SHH signaling pathway induces migration of various cell types including glioblastoma, liver cancer cells, fibroblasts, endothelial cells, monocytes as well as aortic SMCs ([@B42]; [@B130]; [@B121]; [@B29]; [@B161]; [@B25]). PDGF-BB-induced aortic SMC migration is reduced following inhibition of the SHH pathway suggesting a major role of this pathway in aortic SMC migration. Matrix metalloproteinases (MMPs), AKT, and ERK1/2 were demonstrated to play a significant role in inducing migration of human ASM cells ([@B107]) and furthermore in aortic SMC migration. [@B161] demonstrated that recombinant SHH induces activation of AKT as well as ERK1/2. Activation of the SHH signaling pathway induced migration through the induction of AKT-mediated activation of MMP-2 and MMP-9 in both glioblastoma and liver cancer cells ([@B29]; [@B25]). Hence an understanding of the precise functional role of the SHH pathway in ASM migration is of great interest. The dearth of reports regarding the functional role of SHH pathway in ASM migration warrants further assessment and understanding of the role of this signaling pathway.

Crosstalk Between Signal Transduction in ASM Proliferation and Migration {#s7}
========================================================================

Multiple studies have demonstrated that both proliferation and migration of ASM cells can be co-regulated through similar signaling molecules or pathways. Proliferation signaling molecules such as STAT3 and JNK, and also cell cycle proteins such as cyclin D1, p27^Kip1^, and S-phase kinase associated protein-2 (Skp-2), were reported to play a regulatory role in ASM cell migration. Silencing of STAT3 with shRNA has been shown to completely abolish PDGF-induced human ASM cell migration ([@B128]). Rac1, a small GTPase which is also known to promote cytoskeletal reorganization at the leading edge promotes directional cell migration in mouse embryonic fibroblasts through STAT3 regulation ([@B148]). In ASM cells, Rac1 also acts as an upstream activator of JNK as well as cyclin D1 in mediating PDGF-activated STAT3 induction of ASM growth ([@B114]; [@B139]). However, whether Rac1 plays a crucial role in STAT3-mediated ASM migration remains to be determined. The involvement of JNK in cellular migration has been reported in several cell types ([@B164]; [@B168]). Increasing the expression of BRAF-activated noncoding RNA (BANCR) has been demonstrated to induce vascular smooth muscle cell (VSMC) migration through the activation of JNK ([@B82]). Furthermore, inhibition of JNK activity of angiotensin II (Ang II)-induced rat aortic smooth muscle cells (RASMCs) ([@B105]) and serotonin-induced pulmonary artery smooth muscle cells (ASMCs) ([@B155]) suppresses cellular migration. Clearly more mechanistic studies are needed to explain the role of JNK and Rac1 in ASM cell migration.

The role of cell cycle proteins in cellular migration has been acknowledged in various experimental systems. The protein p27^Kip1^ has been shown to inhibit vascular smooth muscle cell migration ([@B143]) and also shown to regulate cell migration through the Rho kinase pathway in which p27^Kip1^ interferes with the interaction between RhoA and its activators ([@B12]). Indeed, the role of Rho kinase in migration of human non-asthmatic ASM cells has been previously demonstrated in which PDGF-induced ASM cell migration was significantly suppressed following treatment with the Rho kinase inhibitor Y27632 ([@B118]). Furthermore, the Rho kinase pathway also regulates proliferation of human non-asthmatic ASM cells in which inhibitors of Rho or Rho-associated kinase were demonstrated to cause significant reduction in proliferation ([@B145]; [@B132]).

As discussed earlier, FAK is known to regulate ASM migration. Apart from this role, [@B16] demonstrated FAK involvement in smooth muscle cell proliferation. In their study Bond and colleagues demonstrated significant inhibition of Skp-2 expression in rat aortic smooth muscle cells transfected with a dominant negative FAK~Y39/F~ mutant. Furthermore, the activity of FAK was reported to be essential in maintaining the stability of Skp-2, thus inducing the progression of cell cycle. Skp-2, is a F-box protein that regulates ubiquitination and proteasome degradation and these findings strengthen the claim that Skp-2 is a downstream target of FAK ([@B16]). Apart from demonstrating the role of Skp-2 in regulating proliferation of rat aortic smooth muscle ([@B16]), [@B30] described similar observations in human bladder smooth muscle cells. In both studies Skp-2 was demonstrated to regulate both rat aortic and human bladder smooth muscle proliferation through the degradation of p27^Kip1^ ([@B16]; [@B30]). It is possible that FAK could possibly induce the degradation of p27^Kip1^ by maintaining the stability of Skp-2, and subsequently induce smooth muscle cell proliferation.

The potential of microRNAs to act as a regulator for both ASM cell proliferation and migration in allergic inflammation and asthma has been highlighted in recent years ([@B124]; [@B104]). MicroRNAs are non-coding RNA comprising ∼22 nucleotides that regulate gene transcription through binding to the 3′-untranslated region (UTR) of the targeted messenger RNAs (mRNAs) ([@B104]). Overexpression of microRNA-638 has been demonstrated to inhibit human ASM cell proliferation and migration through direct targeting of cyclin D1 and neuron-derived orphan receptor 1 (NOR1) expression, whereas NOR1 has been shown to be crucial for human ASM cell migration ([@B152]). The signaling molecules or pathways involved in ASM migration and the crosstalk between proliferative and migratory pathways in ASM are illustrated in the diagram below ([**Figure 2**](#f2){ref-type="fig"}).

![Crosstalk between proliferative and migratory signaling pathways in ASM. The proliferative and migration signaling molecules in ASM are co-related at certain points. MicroRNAs, which include miRNA-638, demonstrated to regulate both ASM proliferation and migration. Solid arrows indicate the associations reported earlier while dotted arrows indicate the possible association that may occur, in which further examination need to be carried out.](fphar-10-01148-g002){#f2}

Signal Transduction Regulation in ASM Apoptosis {#s8}
===============================================

The increase in number of ASM cells in the asthmatic airway is very much dependent upon the balance between cell proliferation and cell death. Apoptosis of ASM cells involves an intricate mechanism that counterbalances the accumulation of ASM mass during airway remodeling. Crosslinking of death receptors such as Fas, tumor necrosis factor receptor-1 (TNFR1), TNF-related apoptosis-inducing ligand receptor 1 (TRAIL-R1), and TRAIL-R2, with their respective ligands leads to apoptosis of proliferating human ASM cells ([@B61]; [@B140]). Apoptosis is initiated *via* intrinsic and extrinsic pathways ([@B43]). The intrinsic pathway can be activated by cellular stress that involves the activation of caspase-9 while the extrinsic pathway is activated by the death receptor which involves the activation of caspase-8 ([@B54]). ASM cell apoptosis can be mediated by both intrinsic and extrinsic pathways and a reduction in cell death has been suggested to contribute to the increased ASM mass. ASM cells isolated from a guinea pig model of asthma exhibited significantly higher survival signals as compared to normal control groups ([@B166]). These survival signals include higher expression of the anti-apoptotic protein Bcl-2 and lower expression of pro-apoptotic proteins as well as downstream effectors such as Bcl-associated X protein (BAX), caspase-9 and caspase-3. These survival signals could be contributors to the increased ASM mass as they reduce the expression level of apoptosis signaling molecules in ASM. However, the direct stimuli that induces these survival signals in ASM have not been defined. Several studies have revealed that ECM proteins and chemokines as well as cell--cell interaction during the inflammation process, reduces the rate of ASM apoptosis *in vitro*, hence inducing ASM remodeling in asthma ([@B50]; [@B126]; [@B59]). Neutrophil elastase, an enzyme known to degrade ECM protein, has been shown to induce apoptosis in human non-asthmatic ASM cells ([@B110]). This finding further confirmed that the ECM protein is crucial in maintaining ASM survival rate during inflammation. As mentioned earlier, the increased number of ASM cells is very much dependent on the balance between cell proliferation and cell apoptosis. Direct interaction between activated CD4^+^ T cell and ASM cell has been shown to induce ASM growth through the increase in proliferation and inhibition of apoptosis in ASM cells isolated from a rat model of asthma ([@B126]). In other systems, studies have demonstrated that not all proliferative stimuli reduce rates of ASM apoptosis. Growth factors, such as EGF, FGF, and PDGF, and pro-inflammatory mediators including bradykinin and histamine, have been shown to increase ASM mass through induction of ASM proliferation without any effect upon the rate of apoptosis in human non-asthmatic ASM cells ([@B50]). It is possible that ASM proliferation and apoptosis could be regulated by distinct mechanisms but at the same time share common signaling molecules.

Crosstalk Between Signal Transduction in ASM Proliferation and Apoptosis {#s9}
========================================================================

ASM proliferation and apoptosis are interconnected through a web of cell cycle regulators and apoptosis stimuli ([@B5]; [@B7]; [@B59]). MAPKs, JAK/STAT and PI3K/AKT signaling pathways, as well as a handful of microRNAs are reported to modulate both cell proliferation and apoptosis ([@B142]; [@B156]; [@B144]; [@B137]). Epithelial-derived chemokines including eotaxin, RANTES, IL-8 and MIP-1β, were demonstrated to induce proliferation and reduce apoptosis in human non-asthmatic ASM cells. The anti-proliferative effect of these chemokines was found to be associated with the activation of ERK1/2 MAPK. However, the signaling pathway involved in these chemokines in reducing ASM apoptosis remains to be determined ([@B59]). On the other hand, the direct role of ERK1/2 upon ASM apoptosis has been reported by [@B7], whereby inhibition of ERK (PD98059) increased the apoptosis percentage of ASM cells from allergen sensitized and challenged mice. This induction was found to be correlated with protein levels of BAX and caspase-3 and reduction of Bcl-2. Furthermore, TNFR1, a death receptor which is known to regulate apoptosis, was shown to promote ASM growth through activation of both p38 and ERK1/2 MAPKs in human non-asthmatic ASM cells ([@B5]). These findings demonstrated that signaling molecules of the apoptosis pathway also regulate ASM proliferation. On the other hand, JNK inhibition using SP600125 had no effect upon ASM apoptosis in both human non-asthmatic and asthmatic ASM cells while the role of p38 upon ASM apoptosis was unclear ([@B31]).

The role of microRNAs in regulating both ASM proliferation and apoptosis has been acknowledged in recent years. Overexpression of microRNA-142 and microRNA-146a, in rat ASM cells and human non-asthmatic ASM cells respectively, were shown to inhibit ASM proliferation and induce ASM apoptosis through direct targeting of EGFR ([@B167]; [@B153]). In addition, microRNA-139-5p and microRNA-216a were demonstrated to exert similar effects in human non-asthmatic ASM cells *via* downregulation of brahma-related gene1 (Brg1) mRNA, a member of the switch/sucrose non-fermentable chromatin-remodeling complex and JAK2 respectively ([@B165]; [@B159]). These findings demonstrated that ASM proliferation and apoptosis can be co-regulated through EGFR, Brg1, and JAK2 with the aid of microRNA-142, microRNA-146a, microRNA-139-5p, and microRNA-216a.

The inhibitory effect of these microRNAs upon EGFR and Brg1 expression was demonstrated to reduce the activation or expression of proliferation-related signaling molecules and anti-apoptotic proteins while promoting pro-apoptotic proteins. Following upregulation of microRNA-142, expression of TGF-β, EGFR, AKT, phosphorylated-AKT, as well as anti-apoptotic proteins including Bcl-2 and B-cell lymphoma-extra-large (Bcl-xl) were reduced while expression of BAX and p21, a cyclin-dependent kinase inhibitor (CKI), were elevated ([@B153]). On the other hand, microRNA-146a has been shown to reduce phosphorylation of ERK, STAT3, and EGFR and also expression of EGFR and Bcl-2, while promoting the activity of caspase 3/7 ([@B167]). Inconsistencies have been noted in the effects of microRNAs in which microRNA-139-5p has been reported to reduce AKT phosphorylation culminating in effects upon ASM proliferation and apoptosis ([@B165]) whereas [@B88] observed reduced AKT phosphorylation only inhibited ASM proliferation without any effect upon apoptosis. Can AKT inhibition alone be sufficient to induce ASM apoptosis? Could microRNA-139-5p targeting other pro-apoptotic molecules be responsible for ASM apoptosis? Indeed more work is needed to further elucidate the role of AKT in ASM apoptosis.

The thermoreceptor, transient receptor potential vanilloid 1 (TRPV1) has also been reported to regulate ASM proliferation and apoptosis. Capsaicin, an agonist of the TRPV1 channel, has been shown to induce proliferation and inhibit apoptosis in rat asthmatic ASM cells while the TRPV1 antagonist capsazepine showed an opposite effect ([@B169]). An increase in intracellular calcium ions following TRPV1 channel activation was suggested to be the cause of enhanced ASM proliferation however, the mechanism by which TRPV1 inhibits ASM apoptosis remains unclear. Elevated intracellular calcium ions has been linked to several cellular processes in ASM, including cell contractility, mobility, and proliferation ([@B11]; [@B55]; [@B84]) of which have been associated with the severity of airway hyperresponsiveness ([@B78]). As such, the role of the TRPV1 channel in reversing increased ASM mass warrants further investigation. Crosstalk between the signaling pathways involved in the regulation of ASM proliferation and apoptosis is illustrated in [**Figure 3**](#f3){ref-type="fig"}.

![Crosstalk between proliferative and apoptotic signaling pathways in ASM. The proliferative and apoptosis signaling molecules in ASM are interrelated at certain points. MicroRNAs, which include miRNA-139-5p, miRNA-216a, and miRNA-142 demonstrated to co-regulate both ASM proliferation and survival. Solid arrows indicate the associations reported earlier while dotted arrows indicate the possible association that may occur, in which further examination need to be carried out. × Indicates the reduced expression level of the molecule.? Indicates the inconsistent findings.](fphar-10-01148-g003){#f3}

Conclusion {#s10}
==========

This communication highlights the signaling pathways and molecules involved in the regulation of ASM hyperplasia as well as the crosstalk that exists between these regulatory molecules. The role of signaling molecules upon ASM proliferation and migration in asthmatic versus non-asthmatic human ASM cells is summarized in [**Table 1**](#T1){ref-type="table"} and animal ASM cells *in vitro* or *in vivo* is summarized in [**Table 2**](#T2){ref-type="table"}. The signal transduction pathways and molecules involved in ASM hyperplasia are interrelated at certain points, however, there are still gaps and questions to be answered. The recent role of microRNAs in mediating ASM proliferation, migration and survival open up new avenues for a better understanding of tissue remodeling in asthma. As such, more work in this area is envisaged and the possible role of microRNAs as novel therapeutic targets is an interesting way forward. The use of bioinformatic tools in mapping out more detailed pathway interactions will further enhance our understanding of the complexity of smooth muscle responses in asthma and subsequently contribute to new approaches and novel drugs to control this disease.

###### 

Summary of findings in studies using human asthmatic versus non-asthmatic ASM cells.

  ---------------------------------------------------------------------------------
              Inducer    Treatment         Non-asthmatic ASM   Asthmatic ASM
  ----------- ---------- ----------------- ------------------- --------------------
  ([@B20])    0.1% FBS   --\               Proliferation ↑\    Proliferation ↑\
                         --\               p-ERK ↑\            p-ERK ↑\*\
                         --\               MKP-1 \#\           MKP-1 \#\
                         ERK (U0126)\      Proliferation ↓\    Proliferation ↓\
                         PI3K (LY294002)   Proliferation ↓     Proliferation ↓

              1% FBS     --\               Proliferation ↑\    Proliferation ↑\*\
                         --\               p-ERK ↑\            p-ERK ↑\*\
                         --\               MKP-1 ↑\            MKP-1 ↑\
                         ERK (U0126)\      Proliferation ↓\    Proliferation ↓\
                         PI3K (LY294002)   Proliferation ↓     Proliferation ↓

              10% FBS    --\               Proliferation ↑\    Proliferation ↑\*\
                         --\               p-ERK ↑\*\          p-ERK ↑\
                         --\               MKP-1 ↑\            MKP-1 ↑\*\
                         ERK (U0126)\      Proliferation ↓\    Proliferation \#\
                         PI3K (LY294002)   Proliferation ↓     Proliferation ↓

  ([@B100])   PDGF       --\               Proliferation ↑\    Proliferation ↑\
                         Sema3E            Proliferation ↓     Proliferation ↓

  ([@B102])   PDGF       --\               Proliferation ↑\    Proliferation ↑\
                         Sema3A\           Proliferation ↓\    Proliferation ↓\
                         Sema3A\           p-GSK3β ↓\          p-GSK3β ↓\
                         Sema3A            p-STAT3 ↓           p-STAT3 ↓

  ([@B3])     CXCL2      --\               Migration ↑\        Migration ↑\*\
                         --\               p-p38 ↑\            p-p38 \#\
                         --\               p-ERK ↑\            p-ERK \#\
                         --                p-PI3K \#           p-PI3K ↑

  ([@B3])     CXCL3      --\               Migration ↑\        Migration ↑\*\
                         --\               p-p38 ↑\            p-p38 \#\
                         --\               p-ERK ↑\            p-ERK \#\
                         --                p-PI3K \#           p-PI3K ↑

  ([@B31])    10% FBS    JNK (SP600125)\   Proliferation ↓\    Proliferation ↓\
                         JNK (SP600125)\   Cyclin D1 ↓\        Cyclin D1 ↓\
                         JNK (SP600125)    Apoptosis \#        Apoptosis \#
  ---------------------------------------------------------------------------------

*↓* Indicates reduction; *↑* indicates increment; \* indicates greater magnitude compared to the other group; \# indicates no difference.

###### 

Summary of findings in studies using non-human model systems.

  ----------------------------------------------------------------------------------------------------------------------------------------------------
  Animal cells/models         Findings
  --------------------------- ------------------------------------------------------------------------------------------------------------------------
  Bovine ASM cells\           PI3K inhibitor (LY294002) completely abolished PDGF-BB and thrombine-induced DNA synthesis
  ([@B151])                   

  Bovine ASM cells\           ERK inhibitor (PD98002) partially inhibited PDGF-BB and thrombin-induced DNA synthesis
  ([@B151])                   

  Bovine ASM cells\           Ras induced full activation of ERK and modest activation of JNK and p38
  ([@B113])                   

  Bovine ASM cells\           PDGF-induced activation of p38 negatively regulated cyclin D1
  ([@B112])                   

  Guinea pig asthma model\    Survival signals in ASM cells significantly elevated compared to control group
  ([@B166])                   

  Mice asthmatic ASM cells\   ERK inhibitor (PD98059) increased the percentage of apoptotic cells in ASM
  ([@B7])                     

  Rat asthma model\           Expression and protein level of β-catenin significantly elevated in ASM cells compared to control group
  ([@B45])                    

  Rat asthmatic ASM cells\    Silencing of β-catenin significantly inhibited migration
  ([@B45])                    

  Rat asthmatic ASM cells\    Direct interaction between activated CD4^+^ T cell and ASM cells induced ASM proliferation and inhibited ASM apoptosis
  ([@B126])                   

  Rat asthmatic ASM cells\    TRPV1 induced ASM proliferation and inhibited ASM apoptosis
  ([@B169])                   
  ----------------------------------------------------------------------------------------------------------------------------------------------------
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